You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. mTOR Substrate Phosphorylation: A New Bioassay for Therapeutics

    SBC: COGNIZANCE BIOMARKERS, LLC            Topic: 107

    DESCRIPTION provided by applicant There are a growing number of human diseases that have been linked to abnormally enhanced activation of the mammalian target of rapamycin mTOR signaling cascade a central pathway governing eukaryotic protein synthesis These include neurodevelopmental disorders associated with epilepsy autism and intellectual disability as well as cancer obesity and dia ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Neurotrophic Agents for Treating Parkinson's Disaese

    SBC: SENEB BIOSCIENCES INC            Topic: 102

    DESCRIPTION provided by applicant Parkinsonandapos s disease PD is a neurodegenerative disorder characterized by motor function and eventually cognitive decline GM depletion is validated as a therapeutic target for Parkinsonandapos s disease PD in clinical studies in which GM replacement stabilized motor function loss and may be disease modifying However GM has poor pharmacologic prop ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. A Tool for Research on Emotion in Naturally Occurring Speech

    SBC: Converspeech LLC            Topic: NLM

    DESCRIPTION provided by applicant A Tool for Research on Emotion in Naturally Occurring Speech It is now widely accepted that defects or limitations in emotion processing underlie many disorders such as anxiety depression bipolar and eating disorders If bio behavioral markers of emotions could be found researchers would have the basis for investigating emotions in both normal mental functi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatment

    SBC: LONGEVICA PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: MOLECULAR EXPRESS, INC            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Antibodies for Biofilm Infections

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIAAA

    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A new treatment for NSAID-associated gastrointestinal damage

    SBC: Anteana Therapeutics Inc            Topic: NIDDK

    DESCRIPTION provided by applicant Non steroidal anti inflammatory drugs NSAIDs are among the most widely consumed pharmaceuticals but their prolonged use causes gastric injury and damage to the small intestine Previous work has shown that anandamide an endogenous endocannabinoid substance produced in the gastrointestinal GI mucosa plays an important role in epithelial homeostasis and re ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government